CN112999317A - Traditional Chinese medicine composition for preventing and treating diabetes and complications thereof, and preparation method and application thereof - Google Patents
Traditional Chinese medicine composition for preventing and treating diabetes and complications thereof, and preparation method and application thereof Download PDFInfo
- Publication number
- CN112999317A CN112999317A CN202110519192.7A CN202110519192A CN112999317A CN 112999317 A CN112999317 A CN 112999317A CN 202110519192 A CN202110519192 A CN 202110519192A CN 112999317 A CN112999317 A CN 112999317A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- medicine composition
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 69
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 43
- 208000002249 Diabetes Complications Diseases 0.000 claims abstract description 21
- 244000060011 Cocos nucifera Species 0.000 claims abstract description 15
- 235000013162 Cocos nucifera Nutrition 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 206010012655 Diabetic complications Diseases 0.000 claims abstract description 10
- 238000009835 boiling Methods 0.000 claims abstract description 10
- 238000002791 soaking Methods 0.000 claims abstract description 8
- 238000001914 filtration Methods 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims description 21
- 244000197580 Poria cocos Species 0.000 claims description 17
- 235000008599 Poria cocos Nutrition 0.000 claims description 17
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 15
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 15
- 241000405414 Rehmannia Species 0.000 claims description 14
- 241000132012 Atractylodes Species 0.000 claims description 13
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 13
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 13
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 13
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 13
- 235000006533 astragalus Nutrition 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 13
- 241000893536 Epimedium Species 0.000 claims description 12
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 12
- 241000218989 Trichosanthes Species 0.000 claims description 12
- 235000018905 epimedium Nutrition 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 241001061264 Astragalus Species 0.000 claims description 9
- 210000004233 talus Anatomy 0.000 claims description 9
- 241000972672 Phellodendron Species 0.000 claims description 7
- 241000559228 Bolboschoenus yagara Species 0.000 claims description 6
- 241000972673 Phellodendron amurense Species 0.000 claims description 6
- 241000202758 Scirpus Species 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 241000045403 Astragalus propinquus Species 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 241000304195 Salvia miltiorrhiza Species 0.000 claims 4
- 239000008280 blood Substances 0.000 abstract description 27
- 210000004369 blood Anatomy 0.000 abstract description 27
- 241000699670 Mus sp. Species 0.000 abstract description 26
- 230000015654 memory Effects 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 5
- 239000009636 Huang Qi Substances 0.000 abstract description 2
- 230000003902 lesion Effects 0.000 abstract description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 abstract 1
- 230000001490 effect on brain Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 29
- 150000001875 compounds Chemical class 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 244000132619 red sage Species 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 230000001603 reducing effect Effects 0.000 description 7
- 210000001320 hippocampus Anatomy 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 208000028698 Cognitive impairment Diseases 0.000 description 5
- 230000003920 cognitive function Effects 0.000 description 5
- 230000000971 hippocampal effect Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000008506 pathogenesis Effects 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 description 4
- 235000001188 Peltandra virginica Nutrition 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 description 4
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000007087 memory ability Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 241000293268 Astragalus chinensis Species 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 201000002824 diabetic encephalopathy Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000006386 memory function Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 239000008517 radix Trichosanthis Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 101150060184 ACHE gene Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000007102 Chronic Brain Damage Diseases 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 239000009022 Jinqi Substances 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 241000951473 Schizonepeta Species 0.000 description 1
- 241000029486 Stephania sinica Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 102000001435 Synapsin Human genes 0.000 description 1
- 108050009621 Synapsin Proteins 0.000 description 1
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 description 1
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 208000018914 glucose metabolism disease Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 210000005227 renal system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N tanshinone IIA Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 208000037820 vascular cognitive impairment Diseases 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/902—Sparganiaceae (Bur-reed family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition for preventing and treating diabetes and diabetic complication cognitive dysfunction, a preparation method and application thereof. The Chinese medicinal composition is prepared from radix astragali, radix rehmanniae Preparata, Poria, cortex Phellodendri, Trichosanthis radix, rhizoma Dioscoreae, herba Epimedii, coconut pulp, rhizoma Sparganii, ramulus Cinnamomi, Saviae Miltiorrhizae radix, and Atractylodis rhizoma by soaking in water, boiling, filtering, and concentrating. The traditional Chinese medicine composition can reduce blood sugar and simultaneously improve the problem of poor space reference memory capacity of mice caused by diabetes cognitive dysfunction, and has a treatment effect on brain function lesion areas of the diabetes cognitive dysfunction.
Description
Technical Field
The invention belongs to the technical field of medicines. In particular to a traditional Chinese medicine composition for preventing and treating diabetes and diabetic complication cognitive dysfunction, a preparation method and application thereof.
Background
Diabetes mellitus is a chronic, systemic and metabolic disease mainly caused by glucose metabolism disorder, and the diabetes mellitus and complications thereof become the seventh leading cause of death in the world. Prolonged exposure to elevated blood glucose levels can lead to complications such as diabetic nephropathy, diabetic cardiomyopathy, diabetic cognitive dysfunction, and diabetic retinopathy. Cognitive dysfunction in diabetes is a cerebral dysfunction caused by metabolic disorder and microangiopathy of diabetes itself, manifested by hypomnesia, decline in learning ability, motor coordination, Impairment of language, comprehension and judgment, and chronic encephalopathy characteristics such as psychiatric disorders (van Gemert T et al. impact on cognitive function in new diabetes mellitus type2diabetes, but not in type 1diabetes. diabetes 2018,61: S416). It is noteworthy that The incidence of cognitive impairment in Diabetic patients is probably 40%, type II diabetes accelerates The cognitive decline of patients, The rate of conversion to dementia in patients with mild cognitive impairment is 10% to 15% per year, and The probability of conversion to dementia after 6 years is even more up to 80% (Yuan et al. Mildcondive cognitive impairment in type2diabetes and related lipid: a review. reviews in The neurosciences 2017,28: 715-723; Ding et al. diabetes rejection and cognitive impairment in diabetes with type2diabetes 2010,59: 2883-2889). At present, the commonly used chemicals for the treatment of diabetic cognitive dysfunction have various degrees of side effects and adverse reactions, such as renal and cardiovascular system impairment, depression, severe skin allergy, gastrointestinal reactions, vertigo and the like (Klimova B et al. Global view on Alzheimer's disease and diabetes mellitis: Threats and diabetes mellitus. Current Alzheimer's disease 2018,15: 1277-. Compared with the traditional Chinese medicine, the traditional Chinese medicine has the characteristics of unique curative effect, high safety, small toxic and side effects and the like, so that the traditional Chinese medicine has obvious advantages and curative effects in treatment of diabetes cognitive dysfunction.
From the perspective of traditional Chinese medicine, the cognitive dysfunction of diabetes belongs to the category of diabetes and dyscrasia, and traditional Chinese medicines with the effects of strengthening brain and improving intelligence or reducing blood sugar can be selected for treatment (Yangli, the influence and mechanism of Jinqi blood sugar reducing tablets on the cognitive dysfunction caused by diabetes, Chinese experimental and prescriptions, 2017,23:146 and 152.). At present, most of the Chinese patent medicines for treating diabetes and complications thereof popular in the market focus on reducing blood sugar, and are also applied aiming at pathogenesis, such as: promoting blood circulation, invigorating qi, resolving phlegm, supporting yang, etc., but the curative effect is not satisfactory. So many Chinese patent medicines are quickly eliminated by the market. For the treatment of DCI, it is necessary to jump out from hyperglycemia itself to find the leading factor, the pathogenesis, that produces and controls brain dysfunction. The doctors of all generations have relatively unified understanding on the pathogenesis of the diabetes, generally consider that the principal is deficiency and the secondary is excess, the deficiency is mainly caused by deficiency of kidney essence, deficiency of marrow and sea, deficiency of yin and dryness-heat, phlegm turbidity obstruction and obstruction of the orifices and blood stasis obstruction of brain collaterals are the main targets, the treatment mainly comprises the treatment methods of tonifying kidney and replenishing essence, tonifying qi and nourishing yin, activating blood and dissolving stasis and resolving phlegm and inducing resuscitation, and the traditional Chinese medicine has complex compatibility and multiple treatment targets, and is considered to have relatively wide prospect in the aspect of preventing and treating the diabetes and the cognitive dysfunction caused by the diabetes.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition for preventing and treating diabetes and diabetic complication cognitive dysfunction. The traditional Chinese medicine composition provided by the invention can obviously improve the cognitive dysfunction of diabetes and can contribute to the treatment and research approach of the cognitive dysfunction of diabetes.
In order to achieve the purpose, the invention provides a traditional Chinese medicine composition for preventing and treating diabetes and diabetic complication cognitive dysfunction, which is prepared from the following raw material medicines in parts by weight:
5-40 parts of astragalus; 5-40 parts of prepared rehmannia root; 5-40 parts of poria cocos; 5-40 parts of salted phellodendron; 5-30 parts of trichosanthes root; 5-30 parts of Chinese yam; 5-30 parts of epimedium; 5-30 parts of coconut pulp; 5-30 parts of scirpus yagara; 5-30 parts of cassia twig; 5-30 parts of salvia miltiorrhiza; 5-30 parts of bighead atractylodes rhizome.
Preferably, the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight:
10-30 parts of astragalus; 10-30 parts of prepared rehmannia root; 10-30 parts of poria cocos; 10-30 parts of salted phellodendron; 10-20 parts of trichosanthes root; 10-20 parts of Chinese yam; 10-20 parts of epimedium; 10-20 parts of coconut pulp; 10-20 parts of scirpus yagara; 10-20 parts of cassia twig; 10-20 parts of salvia miltiorrhiza; 10-20 parts of bighead atractylodes rhizome.
More preferably, the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight:
20 parts of astragalus; 20 parts of prepared rehmannia root; 20 parts of poria cocos; 20 parts of salted phellodendron; 15 parts of trichosanthes root; 15 parts of Chinese yam; 10 parts of epimedium; 10 parts of coconut pulp; 10 parts of scirpus yagara; 10 parts of cassia twig; 10 parts of salvia miltiorrhiza; 10 parts of bighead atractylodes rhizome.
The invention also aims to provide a preparation method of the traditional Chinese medicine composition for preventing and treating diabetes and diabetic complication cognitive dysfunction, and the preparation method comprises the following steps:
mixing the astragalus membranaceus, the prepared rehmannia root, the poria cocos, the salted phellodendron amurense, the trichosanthes root, the Chinese yam, the epimedium herb, the coconut pulp, the scirpus, the cassia twig, the salvia miltiorrhiza and the bighead atractylodes rhizome in parts by weight to obtain a mixture, soaking the mixture in distilled water, heating the mixture to a boiling state, filtering the boiling state by using gauze, and taking part of concentrated solution to dilute the concentrated solution to 1g/mL to obtain the traditional.
Preferably, the amount of the distilled water is 8 times of the mass of the mixture;
the soaking time is 30 min;
the boiling time is 40 min;
the traditional Chinese medicine composition is preserved at the temperature of-20 ℃ before use and is thawed at the temperature of 4 ℃.
The third purpose of the invention is to provide the application of the traditional Chinese medicine composition in preparing the medicine for treating diabetes and diabetic complication cognitive dysfunction.
Preferably, the traditional Chinese medicine composition is prepared into an oral preparation according to a traditional Chinese medicine conventional preparation method.
The invention relates to a compound traditional Chinese medicine (hereinafter, called 'compound consciousness restoring prescription') which is formed by combining 12 medicinal materials of astragalus, prepared rehmannia root, tuckahoe, salted phellodendron bark, trichosanthes root, Chinese yam, epimedium herb, coconut pulp, scirpus, cassia twig, salvia miltiorrhiza and bighead atractylodes rhizome, and is prepared by cutting a Chinese milkvetch root and tuckahoe decoction from the emergency stephania sinica diels prescription as a basic prescription, and the maturity of projects is higher through years of clinical and basic research. The development and production of the strain can certainly become an effective means for treating the diabetic encephalopathy, and the popularization and application of the strain can improve the clinical curative effect of the diabetic encephalopathy, relieve the pain of patients and have good social benefit.
The effects and pharmacological actions of the raw medicinal materials in the invention are as follows:
radix astragali has effects of invigorating qi, consolidating superficial resistance, expelling toxin, expelling pus, promoting urination, and promoting granulation; modern pharmacological research shows that astragalus can not only improve the daily life capacity and cognitive function of mild and moderate AD patients, but also effectively remove free radicals and resist hypoxia, thereby relieving oxidative stress, simultaneously bidirectionally regulating blood sugar, improving glycolipid metabolic disturbance, reducing insulin resistance, and improving cardio-cerebral functions and microcirculation;
the salted cortex Phellodendri has effects of nourishing yin and lowering fire. Modern pharmacological research shows that the salted phellodendron has obvious hypoglycemic effect and can obviously improve the symptoms of diabetic rats;
the prepared rehmannia root can enrich the blood, nourish yin, replenish vital essence and fill marrow, wherein the active ingredient catalpol can be skillfully expressed by up-regulating related regulatory proteins and protein kinases in hippocampal tissues of diabetic rats, including antioxidant stress reaction, so that the morphological change of the hippocampal tissues is improved, the learning and memory ability of the hippocampal tissues is improved, the protective effect of central nerves is further exerted, and the cognitive function of the diabetic rats is improved;
herba Epimedii has effects of invigorating kidney, supporting yang, dispelling pathogenic wind, and removing dampness, and its effective component icariin has effects of increasing blood flow of cerebral vessels, regulating immunity, and delaying aging. Compared with a control group, the mouse treated by the epimedium herb and the major component icariin through gastric perfusion has obviously improved learning and memory abilities, the mechanism of the mouse can improve the expression of AchE and ChAT in hippocampal tissues together with the icariin, and the icariin can increase the activity of superoxide dismutase and preparation degammine peroxidase in the hippocampal tissues and is also beneficial to improving cognitive functions;
cassia twig has the effects of inducing sweat, relieving exterior syndrome, dispelling cold, relieving pain, activating yang, regulating qi, promoting diuresis, eliminating dampness, strengthening spleen and calming heart, and a Chinese patent medicine preparation, namely, cassia twig and poria cocos pill, which takes cassia twig and poria cocos as monarch drugs has a definite curative effect in treating cognitive dysfunction caused by chronic cerebrovascular dysfunction, relieves the cholinergic pathway damage degree, and promotes the improvement of the cognitive function of a patient;
the red sage root has the effects of activating blood and stimulating the menstrual flow, clearing away the heart fire and cooling blood, wherein the tanshinone IIA serving as an effective component has a remarkable clinical curative effect on a patient suffering from vascular cognitive impairment, and can remarkably improve inflammatory stress response, cognitive impairment and nerve functions of the patient;
the bighead atractylodes rhizome has the effects of tonifying spleen and qi, has the main components of volatile oil, lactones and polysaccharides, has an effect on treating diabetes, can effectively improve the relevant indexes of diabetes such as fasting blood sugar, postprandial blood sugar and glycosylated hemoglobin, and can influence the synaptic plasticity to enhance the learning and memory functions and obviously improve the learning and memory capacity of brain-aged mice by up-regulating the expression of synapsin, protein kinase and cyclic adenosine monophosphate response element binding protein;
the modern pharmacological research shows that the trichosanthes root has the function of reducing blood sugar of rats with alloxan diabetes, but has no relevant report on the improvement of cognitive disorder;
the Chinese yam has the effects of tonifying spleen and lung, reinforcing kidney and replenishing vital essence, and the prescription for tonifying kidney, replenishing marrow and activating blood used as the medicine has been reported to treat cognitive dysfunction after cerebral apoplexy in clinic;
coconut pulp has the effects of tonifying qi and strengthening spleen, and scirpus has the effects of strengthening spleen and promoting qi circulation, and the two methods have not been related to the research on the treatment of the cognitive dysfunction of diabetes.
The 'compound refreshment formula' takes the innovative pathogenesis theory of traditional Chinese medicine as guidance: the method takes 'sugar control is not the key of pathogenesis of brain cognitive impairment' as a starting point; the guidance is 'kidney essence deficiency, marrow sea deficiency, yin deficiency and dryness-heat'; the basic treatment method is 'nourishing yin and tonifying qi, and tonifying spleen and kidney'. The decoction is prepared by cutting the Chinese milkvetch root and poria cocos decoction as a basic prescription from the prescription of Qian jin Fang in Stap urgency, has full theoretical basis and reasonable prescription, and is clinically changed from clinic to clinic on the basis of clinical practice. The compound refreshment formula takes astragalus root, tuckahoe, prepared rehmannia root and salted phellodendron bark as monarch drugs; radix trichosanthis and Chinese yam are ministerial drugs; herba Epimedii, coconut pulp, rhizoma Sparganii, ramulus Cinnamomi, Saviae Miltiorrhizae radix, and Atractylodis rhizoma are adjuvant drugs. It is worth mentioning that the rhizoma sparganii with the efficacy of tonifying qi and spleen and the efficacy of tonifying spleen and promoting qi circulation in the traditional Chinese medicine composition provided by the invention is used as an adjuvant drug in a prescription, and although the two drugs have not been researched on the treatment of the cognitive dysfunction of diabetes, the traditional Chinese medicine composition provided by the invention has better treatment effects than a positive drug on the improvement of the learning and memory functions of mice and the improvement of the pathological changes of hippocampus.
The method selects a plurality of groups of parallel experiments to compare weekly fasting glucose data after administration of mice by contrast control, utilizes single-factor variance analysis of a database, and observes the blood glucose reduction effect of a prescription on experimental mice; on the other hand, the Barnes maze experiment is used for trying to judge whether the learning and memory abilities of the traditional Chinese medicine composition on the spatial position sense and the direction sense of the mouse are improved or not, and the improvement effect of the prescription on the cognitive dysfunction of the diabetes is explored. The pathological examination result of the brain slice more intuitively shows the treatment effect of the traditional Chinese medicine composition on the relevant functional areas of the brain.
After being extracted by water, the traditional Chinese medicine composition is prepared into an oral preparation for treating the cognitive dysfunction of diabetes, has the functions of treating the lesion of a brain functional area caused by the cognitive dysfunction of diabetes and improving spatial reference memory capacity, has small toxic and side effects and stable drug effect, and can be used as a candidate drug for treating the cognitive dysfunction of diabetes.
Drawings
Figure 1 is pre-and post-dose glucose results (. P <0.05,. P < 0.001);
figure 2 shows the maze latency results (. P <0.01,. P <0.001, NS no statistical difference);
FIG. 3 is a graph of the maze path for each group of mice;
FIG. 4 is a schematic representation of hippocampus of brain slices from various groups of mice.
Detailed Description
The invention is further described below by way of examples, it being understood that these examples are for illustrative purposes only and in no way limit the scope of the invention.
The experimental procedures used in the following examples are all conventional procedures unless otherwise specified.
Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.
Example 1, a traditional Chinese medicine composition (named compound refreshing decoction) for preventing and treating diabetes and diabetic complication cognitive dysfunction:
weighing the following raw materials of 20g of astragalus membranaceus, 20g of prepared rehmannia root, 20g of poria cocos, 20g of salted phellodendron bark, 15g of trichosanthes root, 15g of Chinese yam, 10g of epimedium, 10g of coconut pulp, 10g of scirpus, 10g of cassia twig, 10g of salvia miltiorrhiza and 10g of bighead atractylodes rhizome (the raw materials are purchased from Beijing Tongrentang Harbin pharmacy Limited liability company and all meet the standard of Chinese pharmacopoeia).
The preparation method of the traditional Chinese medicine composition comprises the following steps:
(1) mixing the raw materials, soaking in cold water (8 times of water) for 30min, heating to boil, and keeping slightly boiling for 40 min.
(2) Filtering with gauze, diluting part of the concentrated solution to 1g/mL, bottling, storing in refrigerator at-20 deg.C, and thawing in refrigerator at 4 deg.C 1 day before administration.
Example 2, a traditional Chinese medicine composition for preventing and treating diabetes and diabetic complication cognitive dysfunction:
weighing 25g of astragalus mongholicus, 25g of prepared rehmannia root, 25g of poria cocos, 25g of salted cortex phellodendri, 20g of radix trichosanthis, 20g of Chinese yam, 15g of herba epimedii, 15g of coconut pulp, 15g of schizonepeta, 15g of cassia twig, 15g of salvia miltiorrhiza and 15g of bighead atractylodes rhizome (the medicinal materials are purchased from Beijing Tongrentang Harbin pharmacy Limited liability company and all meet the standard of Chinese pharmacopoeia).
The preparation method of the traditional Chinese medicine composition comprises the following steps:
(1) mixing the raw materials, soaking in cold water (8 times of water) for 30min, heating to boil, and keeping slightly boiling for 40 min.
(2) Filtering with gauze, diluting part of the concentrated solution to 1g/mL, bottling, storing in refrigerator at-20 deg.C, and thawing in refrigerator at 4 deg.C 1 day before administration.
Example 3, a traditional Chinese medicine composition for preventing and treating diabetes and diabetic complication cognitive dysfunction:
weighing the following raw material medicines of 15g of astragalus, 15g of prepared rehmannia root, 15g of tuckahoe, 15g of salted phellodendron bark, 10g of trichosanthes root, 10g of yam, 5g of epimedium, 5g of coconut pulp, 5g of scirpus, 5g of cassia twig, 5g of salvia miltiorrhiza and 5g of bighead atractylodes rhizome (the raw materials are purchased from Beijing Tongrentang Harbin drugstore, Limited liability company and all meet the standard of Chinese pharmacopoeia).
The preparation method of the traditional Chinese medicine composition comprises the following steps:
(1) mixing the raw materials, soaking in cold water (8 times of water) for 30min, heating to boil, and keeping slightly boiling for 40 min.
(2) Filtering with gauze, diluting part of the concentrated solution to 1g/mL, bottling, storing in refrigerator at-20 deg.C, and thawing in refrigerator at 4 deg.C 1 day before administration.
Test example: the medicine effect and action mechanism of the traditional Chinese medicine composition (called compound consciousness restoring decoction) prepared in the embodiment 1 on the diabetes cognitive dysfunction mouse model are applied
First, experimental material and method
1. Experimental drugs and reagents
Test drugs (compound refreshment soup prepared in example 1); the positive drug rosiglitazone was purchased from Shanghai leaf company.
2. Experimental methods
(1) In the experiment, db/db mice of 8-10 weeks old are used, female mice are female mice, the SPF grade is 40 mice, and the mice are purchased from Nanjing Junke bioengineering Co. Animals were housed at the pharmaceutical school of Harbin medical university.
(2) Animal grouping and dosing: after db/db mice are adaptively fed for one week, the mice are randomly divided into 4 groups according to body lipid amount, namely a Control group (Control), a Model group (Model), a compound refreshment soup administration group (FFXNT) and a Positive medicine group (Positive), wherein each group comprises 10 mice. And constructing a diabetes cognitive dysfunction model by adopting high-fat diet.
Gavage was performed using a 1ml syringe, 17: 00 the gavage operation was performed for 6 weeks. The dosage of the Chinese herbal compound is set by converting the daily clinical medication dosage of a human into a mouse, the concentration is 1g/mL, and the dosage is 0.4 mL. The control group was intragastrically infused with deionized water.
(3) Measurement of fasting blood glucose: fasting plasma glucose was measured in all mice every week after the first dose, the mice were fasted 19 nights before the measurement, and plasma glucose was measured 7 morning next day, and blood was collected from the tail of the mice under the standard conditions of temperature and humidity to obtain Fasting Plasma Glucose (FPG)
(4) The Barnes maze method is used for observing the spatial reference memory capacity maze of the mouse, utilizes the habit design of the pleased darkness and the avoidance of the rodent, and enables the animal to search for the dark box below the hole of the appointed position in the specified time through strong light irradiation and noise stimulation. The experiment is divided into a training period and a testing period, the testing is carried out after continuous training for a plurality of days, the time, the total distance, the speed and the like of the animal entering a dark box and the times of entering the wrong hole are recorded to reflect the spatial reference memory capacity of the animal, and the working memory of the animal can also be measured by recording the times of repeatedly entering the wrong hole. Note that: the maze is rotated randomly after each training, so that the positions of the maze are different in two consecutive days, but the position of the target box is not changed. When the animal wanders beside other holes, the head of the animal stretches into the hole, and the eyes of the animal are lower than the edge of the platform, the escape error is judged.
(5) After experimental data are obtained, heart, liver, spleen, lung, kidney, pancreatic islet and brain tissues of the mice are taken out and stored for later use.
(6) The samples to be inspected are fixed by 4 percent paraformaldehyde, and after the fixed state is good, the samples are trimmed, dehydrated, embedded, sliced, dyed and mounted according to the SOP program of the unit pathological experiment detection, and finally qualified sample wafers are microscopically inspected.
(7) And (3) browsing the section under a microscope or browsing the digital section, observing the condition of the tissue section in detail under different times, describing basic pathological changes in the section such as congestion, extravasated blood, hemorrhage, edema, degeneration, necrosis, hyperplasia, fibrosis, organization, granulation tissue, inflammatory change and the like in text, and reflecting the difference between the sections.
(8) The results were statistically processed:
firstly, before administration, fasting blood glucose values of mice of different groups are respectively measured to determine whether the model is successfully constructed.
② measuring the fasting blood sugar of the mouse every week and recording to determine the blood sugar reducing effect. Performing data statistical analysis by using Graphpad prism 9.0 software, wherein the measured data is expressed by mean +/-standard deviation (x +/-s); the multi-group comparison adopts One-way ANOVA (One-way ANOVA), and the inter-group comparison adopts t test; differences with P <0.05 were statistically significant. And (5) drawing a chart and performing statistical analysis.
Second, experimental results
The results shown in figure 1 show that the average blood sugar values of the pre-administration model group and the compound refreshing decoction administration group both reach the level of diabetes (the blood sugar value is 11.1mmol/L), and the successful construction of the diabetes model is proved.
The blood sugar results after six weeks of administration show that the positive drug and the compound refreshing decoction have obvious blood sugar reducing effects compared with the model group.
According to the results shown in fig. 2, after training, compared with the model group, the maze latency of the compound refreshing decoction group is obviously shortened, the cognitive dysfunction of the mouse is improved (P is less than 0.001), and the cognitive dysfunction of the positive medicine group mouse is not obviously improved.
The results shown in fig. 3 show that compared with the maze track of the mice in the model group, the maze track path of the mice in the compound refreshing decoction administration group is clear, and the target orifice can be found in a shorter path.
The results shown in fig. 4 show that the hippocampus in the control group has abundant and closely arranged neurons, normal neuron morphological structure, clear nucleus and cytoplasm boundary, obvious nucleolus and no obvious inflammation; neuron shrinkage, cell staining deepening and unclear nuclear cytoplasm boundary (black arrows) can be seen in all the hippocampus areas of the model group; the hippocampus of the compound refreshing decoction group has rich number of neurons, compact arrangement, normal neuron morphological structure, clear nucleus and cytoplasm boundary, obvious nucleolus and no obvious inflammation; the hippocampus CA1 region of the positive drug group showed a small amount of neuron shrinkage, a deeper cell staining, and unclear nuclear cytoplasm demarcation (black arrows).
In conclusion, the traditional Chinese medicine composition can reduce the blood sugar of db/db mice and reduce the body weight of the mice; can also improve the spatial reference memory capacity of db/db mice, has certain treatment effect on the brain functional areas of the mice which are affected by diabetes cognitive dysfunction, and has explorable clinical medical prospect.
The foregoing describes preferred embodiments of the present invention, but is not intended to limit the invention thereto. Modifications and variations of the embodiments disclosed herein may be made by those skilled in the art without departing from the scope and spirit of the invention.
Claims (7)
1. The traditional Chinese medicine composition for preventing and treating diabetes and diabetic complication cognitive dysfunction is characterized by being prepared from the following raw material medicines in parts by weight:
5-40 parts of astragalus; 5-40 parts of prepared rehmannia root; 5-40 parts of poria cocos; 5-40 parts of salted phellodendron; 5-30 parts of trichosanthes root; 5-30 parts of Chinese yam; 5-30 parts of epimedium; 5-30 parts of coconut pulp; 5-30 parts of scirpus yagara; 5-30 parts of cassia twig; 5-30 parts of salvia miltiorrhiza; 5-30 parts of bighead atractylodes rhizome.
2. The traditional Chinese medicine composition according to claim 1, which is prepared from the following raw materials in parts by weight:
10-30 parts of astragalus; 10-30 parts of prepared rehmannia root; 10-30 parts of poria cocos; 10-30 parts of salted phellodendron; 10-20 parts of trichosanthes root; 10-20 parts of Chinese yam; 10-20 parts of epimedium; 10-20 parts of coconut pulp; 10-20 parts of scirpus yagara; 10-20 parts of cassia twig; 10-20 parts of salvia miltiorrhiza; 10-20 parts of bighead atractylodes rhizome.
3. The traditional Chinese medicine composition according to claim 1, which is prepared from the following raw materials in parts by weight:
20 parts of astragalus; 20 parts of prepared rehmannia root; 20 parts of poria cocos; 20 parts of salted phellodendron; 15 parts of trichosanthes root; 15 parts of Chinese yam; 10 parts of epimedium; 10 parts of coconut pulp; 10 parts of scirpus yagara; 10 parts of cassia twig; 10 parts of salvia miltiorrhiza; 10 parts of bighead atractylodes rhizome.
4. A method for preparing a Chinese medicinal composition according to any one of claims 1 to 3, wherein: the preparation method comprises the following steps:
mixing the astragalus membranaceus, the prepared rehmannia root, the poria cocos, the salted phellodendron amurense, the trichosanthes root, the Chinese yam, the epimedium herb, the coconut pulp, the scirpus, the cassia twig, the salvia miltiorrhiza and the bighead atractylodes rhizome in parts by weight to obtain a mixture, soaking the mixture in distilled water, heating the mixture to a boiling state, filtering the boiling state by using gauze, and taking part of concentrated solution to dilute the concentrated solution to 1g/mL to obtain the traditional.
5. The method of claim 4, wherein: the amount of the distilled water is 8 times of the mass of the mixture;
the soaking time is 30 min;
the boiling time is 40 min;
the traditional Chinese medicine composition is preserved at the temperature of-20 ℃ before use and is thawed at the temperature of 4 ℃.
6. Use of the Chinese medicinal composition of any one of claims 1-3 in the preparation of a medicament for treating diabetes and its complications, diabetes cognitive dysfunction.
7. Use according to claim 6, characterized in that: the traditional Chinese medicine composition is prepared into an oral preparation according to a traditional Chinese medicine conventional preparation method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110519192.7A CN112999317B (en) | 2021-05-12 | 2021-05-12 | Traditional Chinese medicine composition for preventing and treating diabetes and complications thereof, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110519192.7A CN112999317B (en) | 2021-05-12 | 2021-05-12 | Traditional Chinese medicine composition for preventing and treating diabetes and complications thereof, and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112999317A true CN112999317A (en) | 2021-06-22 |
| CN112999317B CN112999317B (en) | 2022-03-18 |
Family
ID=76380744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110519192.7A Active CN112999317B (en) | 2021-05-12 | 2021-05-12 | Traditional Chinese medicine composition for preventing and treating diabetes and complications thereof, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112999317B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103463358A (en) * | 2012-06-07 | 2013-12-25 | 苏州法莫生物技术有限公司 | Traditional Chinese medicine compound preparation for treatment of diabetes and preparation method thereof |
| CN106620475A (en) * | 2017-01-12 | 2017-05-10 | 山东省中医药研究院 | Traditional Chinese medicine composition for preventing and treating cognitive disorder caused by diabetes mellitus, and preparation method of traditional Chinese medicine composition |
| CN108452160A (en) * | 2018-07-02 | 2018-08-28 | 汝州市济仁糖尿病医院 | A kind of ginseng stilbene Siberian cocklebur art preparation of breath in heptan training pancreas therapy treatment diabetes |
-
2021
- 2021-05-12 CN CN202110519192.7A patent/CN112999317B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103463358A (en) * | 2012-06-07 | 2013-12-25 | 苏州法莫生物技术有限公司 | Traditional Chinese medicine compound preparation for treatment of diabetes and preparation method thereof |
| CN106620475A (en) * | 2017-01-12 | 2017-05-10 | 山东省中医药研究院 | Traditional Chinese medicine composition for preventing and treating cognitive disorder caused by diabetes mellitus, and preparation method of traditional Chinese medicine composition |
| CN108452160A (en) * | 2018-07-02 | 2018-08-28 | 汝州市济仁糖尿病医院 | A kind of ginseng stilbene Siberian cocklebur art preparation of breath in heptan training pancreas therapy treatment diabetes |
Non-Patent Citations (6)
| Title |
|---|
| 余瀛鳌等: "《宋以前医方选》", 30 June 2007, 中医古籍出版社 * |
| 周莉萍等: "中药防治糖尿病认知功能障碍的实验研究进展", 《中国实验方剂学杂志》 * |
| 孙丰雷: "健脾降糖饮治疗2型糖尿病35例", 《山东中医药大学学报》 * |
| 张露等: "糖尿病认知功能障碍研究进展", 《世界科学技术-中医药现代化》 * |
| 杨丽等: "金芪降糖片对糖尿病引发的认知功能障碍的影响及机制", 《中国实验方剂学杂志》 * |
| 陈友平等: "《人参治病亦养生》", 31 January 2007, 上海科学技术文献出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112999317B (en) | 2022-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101357219B (en) | Medicine for treating chronic hepatitis B | |
| CN101411760B (en) | Novel use of plants in sorbus malus group of malus | |
| CN1558768A (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
| CN102100758B (en) | Qingpeng gel for relieving pain and subdhing swelling and preparation method thereof | |
| CN101095900B (en) | Sichuan chrysanthemum pain-relieving capsule and method for preparing the same | |
| CN103223069A (en) | Traditional Chinese medicine composition for treating hepatitis | |
| CN103006989B (en) | Medical composition for treating diabetic nephropathy | |
| CN112999317B (en) | Traditional Chinese medicine composition for preventing and treating diabetes and complications thereof, and preparation method and application thereof | |
| Gao et al. | Tibetan medicines and Tibetan prescriptions for the treatment of diabetes mellitus | |
| CN103432420B (en) | A kind of Chinese medicine composition for the treatment of diabetes and preparation method thereof and detection method | |
| CN103520646B (en) | Chinese medicine composition for treating depression and preparation method of Chinese medicine composition | |
| CN103006831B (en) | Blood platelet raising capsules, namely Chinese herbal combination, and preparation method of capsules | |
| CN103385931B (en) | Blood-sugar-lowering medicine composition | |
| CN101732585A (en) | Medicinal composition for treating migraine, preparation method and application thereof | |
| Liang et al. | Treatment of diabetic retinopathy with herbs for tonifying kidney and activating blood circulation: A review of pharmacological studies | |
| CN104042928B (en) | A kind of pharmaceutical composition for treating diabetes and its production and use | |
| CN107648565A (en) | A kind of pharmaceutical composition for treating depression and preparation method thereof | |
| CN109247528A (en) | It is a kind of to subtract the composition and its application of effect for alleviating thyroid nodule and first | |
| CN112451618A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy | |
| CN1463734A (en) | A prepared Chinese medicine for treating diabetes mellitus and method for preparing same | |
| CN108743885A (en) | A kind of Chinese medicine and preparation method thereof for treating Diabetic Macrovascular Complications | |
| CN1315499C (en) | Medicine for treating diabetes and its complications and process for preparing the same | |
| CN104605051A (en) | Double hemp-folium cortex eucommiae tea and preparing method thereof | |
| CN108686094A (en) | A kind of Traditional Chinese medicine for decreasing blood sugar and preparation method thereof | |
| CN109999155B (en) | Traditional Chinese medicine composition for treating Alzheimer disease and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |